Study record
Leukocyte telomere length and mortality in 64,637 individuals (Rode et al., 2015)
Human observational cohort — biomarker association (contested)
Two caveats govern every page on this site. (1) Telomere length is a contested aging biomarker — it is measured differently by different methods, varies between tissues, and "longer" is not straightforwardly "healthier"; changing a telomere-length or telomerase-activity number in a trial is not the same as slowing human aging. (2) Activating telomerase is not risk-free — telomerase is silenced in most somatic cells and reactivated in most cancers, so its activation raises an unresolved cancer-risk question. Tellingly, the only FDA-approved telomerase drug — imetelstat (RYTELO, 2024) — inhibits telomerase to treat cancer (lower-risk MDS), the opposite direction from the anti-aging "activation" narrative.
○ Evidence tier 4 — Human pilot / observational — biomarker
Record
| Design | Prospective observational cohort (leukocyte telomere length ↔ mortality association) |
| N | 64637 |
| DOI | 10.1093/jnci/djv074 |
| Citation status | doi verified via Crossref 2026-07-12 (J Natl Cancer Inst 2015;107(6):djv074, Rode, Nordestgaard, Bojesen, 'Peripheral Blood Leukocyte Telomere Length and Mortality Among 64 637 Individuals From the General Population'). PMID not separately fetched (DOI is the confirmed primary identifier). |
Five-qualifier claim
| Species / population | 64,637 individuals from the Danish general population (Copenhagen General Population Study / Copenhagen City Heart Study) — an observational cohort. |
| Exposure, route, schedule | No intervention — leukocyte telomere length measured (qPCR) and related to outcomes; this is an association study. |
| Comparator / duration | Prospective cohort with long-term mortality follow-up; genetic (Mendelian-randomization) analyses included. |
| Endpoint / numeric result | Shorter leukocyte telomere length was associated with higher all-cause mortality, but the association was modest and, in genetic analyses, largely explained by factors other than a direct causal effect of telomere length itself. |
| What it did NOT establish | An observational association, not causation and not an intervention. It illustrates that telomere length is a modest, confounded, contested biomarker — not a lever proven to change health when altered. |
Primary reference
https://doi.org/10.1093/jnci/djv074
Exact identifier confirmed against the primary record via Crossref/ClinicalTrials.gov where stated in the citation status; anything marked needs_primary_fulltext is not yet confirmed.